Meihua International Medical Technologies Approves $3M Share Repurchase Plan
Ticker: MHUAF · Form: 6-K · Filed: Jul 1, 2024 · CIK: 1835615
| Field | Detail |
|---|---|
| Company | Meihua International Medical Technologies Co., Ltd. (MHUAF) |
| Form Type | 6-K |
| Filed Date | Jul 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-repurchase, board-approval, company-update
TL;DR
Meihua Intl Medical Tech ($MHUA) authorized up to $3M buyback plan, signaling confidence.
AI Summary
Meihua International Medical Technologies Co., Ltd. announced on June 26, 2024, that its board of directors approved a share repurchase plan of up to $3 million of the Company's ordinary shares. This plan allows the Company to buy back its own stock in the open market or through private transactions over a period of 12 months.
Why It Matters
A share repurchase plan can signal management's confidence in the company's valuation and potentially increase earnings per share by reducing the number of outstanding shares.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a share repurchase plan, which is a common corporate action and does not inherently indicate significant new risks.
Key Numbers
- $3.0M — Share Repurchase Authorization (Maximum amount the company is authorized to spend on repurchasing its shares.)
Key Players & Entities
- Meihua International Medical Technologies Co., Ltd. (company) — Company announcing share repurchase plan
- $3 million (dollar_amount) — Maximum value of the share repurchase plan
- June 26, 2024 (date) — Date the board of directors approved the share repurchase plan
FAQ
What is the total amount authorized for the share repurchase plan?
The company has authorized a share repurchase plan of up to $3 million.
When was the share repurchase plan approved?
The board of directors approved the share repurchase plan on June 26, 2024.
What is the duration of the share repurchase plan?
The filing states the plan allows for repurchases over a period of 12 months.
What is the company's principal executive office address?
The principal executive office is located at 88 Tongda Road, Touqiao Town, Guangling District, Yangzhou, 225000, People's Republic of China.
Does the company file annual reports under Form 20-F or 40-F?
The company indicates it files annual reports under cover of Form 20-F.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-07-01 06:08:16
Key Financial Figures
- $3 million — adopt a share repurchase plan of up to $3 million of the Company’s outstanding ordi
Filing Documents
- ea0208429-6k_meihua.htm (6-K) — 14KB
- ea020842901ex99-1_meihua.htm (EX-99.1) — 49KB
- ea020842901ex99-2_meihua.htm (EX-99.2) — 60KB
- ea020842901ex99-3_meihua.htm (EX-99.3) — 50KB
- ea020842901ex99-4_meihua.htm (EX-99.4) — 11KB
- ex99-4_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-057439.txt ( ) — 189KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Meihua International Medical Technologies Co., Ltd. Dated: July 1, 2024 By: /s/ Xin Wang Name: Xin Wang Title: Chief Executive Officer (Principal Executive Officer) 2